Subscribe to Newsletter
Manufacture Small Molecules, Bioprocessing - Single Use Systems, Advanced Medicine, Digital Technologies

Games, Drugs, and Rock ‘n’ Roll

When I started writing about the industry (quite some years ago…), small molecule drugs were still prominent in discussions, monoclonal antibodies were on an undeniable upward trajectory, and cell and gene therapies were little more than pipedreams. Continuous processing was beginning to be tentatively mentioned outside of academia. And there were conversations about whether the industry would ever accept single-use systems. 

On reflection, it’s quite surprising where we are today. Single-use tech is standard. Suppliers are developing continuous tech for bioprocessing. And “cell and gene” is one of the hottest topics around.

Perhaps even more surprising, for our January/February print issue, we ran a cover feature on video games. Yes, video game tech is now relevant to pharma. Hard to imagine? Video games are a highly popular entertainment choice – so supporting patients using games and digital therapeutics is not as wild as it might sound. Consumer brain training games have existed for years, but Akili Interactive has gone one important step further. Their game, EndeavorRx, has received approval from the FDA to be prescribed to treat children with ADHD. Think of the game itself as a dosage form. You can read more about this – and other intriguing examples of video game tech and how it could affect medicine and pharmaceutical quality in our feature

What about traditional medicine making? Traditional API-based pills and tablets are not going away. Neither are large molecules, even though some of the spotlight has been lost to cell therapy. My aim with every issue of The Medicine Maker is to connect you all by providing a high-level view of what is going on across the entire industry – including whatever interesting (or controversial) developments are likely to shape the future, whether in politics, video games, or something even more unexpected.

To ensure you don’t miss key details in the big picture, we have introduced “Core Topics,” featuring content for our print issues specifically sourced for those of you in small molecule manufacturing, bioprocessing, and cell and gene. Check it out in our Jan/Feb print issue, which can be downloaded here

As ever, if you have something to contribute to our Core Topics or elsewhere for The Medicine Maker then please get in touch: [email protected].

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine